FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a pharmaceutical composition applicable for treating Down syndrome mediated by Dyrkla activity. The composition contains a compound of formula I in an effective amount and a pharmaceutically acceptable carrier. In Formula I, each R1 is independently specified in a group consisting of 3 and F; R2 represents S; R3 represents (CH2)m, wherein m is equal to 3; R4 represents H; R6 represents H; each R8 is independently -OR9 and each R9 independently represents 3 or C1-6alkyl.
EFFECT: invention refers to a method of treating Down syndrome mediated by Dyrkla activity.
7 cl, 1 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD AND COMPOSITION FOR STIMULATING NEUROGENESIS AND INHIBITING NEURON DEGENERATION | 2006 |
|
RU2440346C2 |
METHODS AND COMPOSITIONS FOR STIMULATION OF NEUROGENESIS AND INHIBITION OF NEURON DEGENERATION WITH USING ISOTHIAZOLOPYRIMIDINONES | 2008 |
|
RU2521333C2 |
METHODS FOR TREATING INFLAMMATION, AUTOIMMUNE DISORDERS AND PAIN | 2014 |
|
RU2669800C2 |
2-S-BENZYLSUBSTITUTED PYRIMIDINES AS CRTH2 ANTAGONISTS | 2008 |
|
RU2491279C2 |
OPHTHALMIC PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2818087C2 |
GSK-3 INHIBITORS | 2006 |
|
RU2449998C2 |
COMPOSITIONS FOR TREATING INFLAMMATION AND METHOD OF TREATING INFLAMMATION | 2010 |
|
RU2543720C2 |
ORGANIC COMPOUNDS | 2019 |
|
RU2809023C2 |
TREATING MALIGNANT TUMOURS USING MODULATORS OF PI3-KINASE ISOFORMS | 2013 |
|
RU2702908C2 |
COMBINATIONS CONTAINING TRANSDUCTION SIGNAL INHIBITOR AND EPOTILONE DERIVATIVE | 2002 |
|
RU2313345C2 |
Authors
Dates
2015-04-27—Published
2010-09-22—Filed